Gold nanoparticles (AuNPs) are revolutionizing drug delivery with their unique physicochemical properties, high biocompatibility, and tunable surface functionality. As a leader in nanomedicine innovation, Litchlab has developed an advanced gold nanoparticle-based drug delivery platform that enhances tumor targeting, gene therapy efficiency, and immunotherapy precision.

Key Advantages of Litchlab’s Gold Nanoparticle Drug Delivery Technolog

1. Photothermal & Photodynamic Therapy (PTT/PDT) for Enhanced Tumor Treatment

Gold nanoparticles exhibit a localized surface plasmon resonance (LSPR) effect, enabling them to absorb near-infrared (NIR) light and convert it into localized heat (PTT) or reactive oxygen species (PDT), enhancing cancer treatment efficacy.

Litchlab’s NIR-Responsive Therapy:
✅ Photothermal Therapy (PTT): NIR laser triggers heat generation (42-45°C), inducing tumor cell apoptosis while improving chemotherapy drug penetration.
✅ Photodynamic Therapy (PDT): Surface-modified AuNPs carrying photosensitizers (e.g., porphyrins, phthalocyanines) generate reactive oxygen species (ROS) upon light activation, selectively destroying tumor cells.
✅ Immunogenic Cell Death (ICD) Enhancement: PTT/PDT induces tumor-associated antigen (TAA) release, boosting dendritic cell (DC) activation and T-cell immune response, synergizing with immunotherapy.

Applications: Suitable for hard-to-treat solid tumors (e.g., breast cancer, melanoma, glioblastoma), augmenting chemotherapy, radiotherapy, and immune checkpoint blockade.

2. Precision Targeting with Surface-Functionalized Gold Nanoparticles

Litchlab utilizes highly controlled surface engineering techniques to conjugate monoclonal antibodies (mAbs), peptides, aptamers, and glycan ligands to AuNPs, enhancing their disease-specific targeting capabilities.

Litchlab’s Targeted Drug Delivery Strategies:
✅ Ligand-Receptor Targeting: Functionalized ligands (e.g., RGD peptides, folic acid, galectin-1 ligands) improve receptor-specific uptake (e.g., αvβ3 integrin, folate receptor).
✅ Antibody-Conjugated AuNPs: Site-specific mAb-AuNP conjugation (via EDC/NHS, Maleimide linkers) delivers payloads precisely to cancer cells, minimizing off-target effects.
✅ Blood-Brain Barrier (BBB) Penetration: Modified AuNPs conjugated with TAT, Angiopep-2, or lactosyl derivatives facilitate drug transport into the brain, enabling treatments for neurodegenerative diseases (Alzheimer’s, Parkinson’s, glioblastoma).

Application Areas: HER2+ breast cancer, EGFR-mutated lung cancer, CD44+ pancreatic cancer, glioblastoma (GBM), increasing specificity and reducing toxicity.

3. Gold Nanoparticles as RNA Drug Carriers for Gene Therapy

RNA-based therapeutics (siRNA, mRNA, ASO) face challenges such as rapid degradation and low intracellular uptake. Litchlab employs electrostatic adsorption, covalent bonding, and hydrophobic interactions to protect and efficiently deliver RNA therapeutics using AuNPs.

Litchlab’s RNA Delivery Optimization:
✅ Nuclease Protection: Surface-modified AuNPs with polylysine or polyamine coatings prevent RNA degradation and enhance in vivo stability.
✅ pH-Responsive Release: Acid-sensitive linkers trigger RNA release in endosomal compartments, increasing intracellular delivery efficiency.
✅ CRISPR/Cas9 Delivery: Gold nanoparticle complexes efficiently co-deliver sgRNA and Cas9 mRNA, enhancing gene editing precision.

Applications: Rare genetic disorders, RNA vaccines, cancer RNAi therapies.

4. Enhancing Vaccine Efficacy with Gold Nanoparticle-Based Adjuvants

Gold nanoparticles serve as potent vaccine carriers, improving antigen presentation and boosting immune responses. Litchlab has developed a gold nanoparticle adjuvant system (AuNP-Adjuvant) that enhances protein, mRNA, and DNA vaccine efficacy.

Litchlab’s Immunotherapy & Vaccine Innovations:
✅ Adjuvant Effect: AuNPs act as TLR agonist carriers (CpG, Poly I:C), activating dendritic cells (DCs) and promoting strong immune responses.
✅ Antigen Co-Delivery: Co-formulation of mRNA with AuNPs enhances translation efficiency and immune activation.
✅ Sustained Release Kinetics: Controlled antigen release improves long-term immune memory formation.

Application Areas: mRNA vaccines (COVID-19, cancer vaccines), protein-based vaccines (HBV, influenza), and tumor immunotherapy.

Litchlab’s Gold Nanoparticle Drug Delivery: Driving Innovation Across Therapeutic Areas

Litchlab: Pioneering Gold Nanoparticle Drug Delivery for the Future of Precision Medicine

Precision targeting for enhanced therapeutic efficacy
Light-activated nanoparticle therapy for selective tumor destruction
Optimized RNA delivery for next-generation gene therapies
Innovative vaccine platforms for superior immune activation

For more information, please feel free to contact us at:  

E-Mail:RD2@Litchlab.com